1.Role of Androgen Receptor in Prostate Cancer: A Review
Kazutoshi FUJITA ; Norio NONOMURA
The World Journal of Men's Health 2019;37(3):288-295
Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding domain, hinge region, and ligand-binding domain. AR plays pivotal roles in prostate cancer, especially castration-resistant prostate cancer (CRPC). Androgen deprivation therapy can suppress hormone-naïve prostate cancer, but prostate cancer changes AR and adapts to survive under castration levels of androgen. These mechanisms include AR point mutations, AR overexpression, changes of androgen biosynthesis, constitutively active AR splice variants without ligand binding, and changes of androgen cofactors. Studies of AR in CRPC revealed that AR was still active in CRPC, and it remains as a potential target to treat CRPC. Enzalutamide is a second-generation antiandrogen effective in patients with CRPC before and after taxane-based chemotherapy. However, CRPC is still incurable and can develop drug resistance. Understanding the mechanisms of this resistance can enable new-generation therapies for CRPC. Several promising new AR-targeted therapies have been developed. Apalutamide is a new Food and Drug Administration-approved androgen agonist binding to the ligand-binding domain, and clinical trials of other new AR-targeted agents binding to the ligand-binding domain or N-terminal domain are underway. This review focuses on the functions of AR in prostate cancer and the development of CRPC and promising new agents against CRPC.
Androgen Antagonists
;
Castration
;
Dihydrotestosterone
;
Drug Resistance
;
Drug Therapy
;
Humans
;
Point Mutation
;
Prostate
;
Prostatic Neoplasms
;
Receptors, Androgen
;
Receptors, Steroid
;
Testosterone
2.Emerging Relationship between the Gut Microbiome and Prostate Cancer
Makoto MATSUSHITA ; Kazutoshi FUJITA ; Koji HATANO ; Marco A. DE VELASCO ; Akira TSUJIMURA ; Hirotsugu UEMURA ; Norio NONOMURA
The World Journal of Men's Health 2023;41(4):759-768
The human gut microbiota changes under the influence of environmental and genetic factors, affecting human health. Extensive studies have revealed that the gut microbiome is closely associated with many non-intestinal diseases. Among these, the influence of the gut microbiome on cancer biology and the efficacy of cancer therapy has attracted much attention. Prostate cancer cells are affected by direct contact with the microbiota of local tissues and urine, and a relationship between prostate cancer cells and the gut microbiota has been suggested. In the human gut microbiota, bacterial composition differs depending on prostate cancer characteristics, such as histological grade and castration resistance. Moreover, the involvement of several intestinal bacteria in testosterone metabolism has been demonstrated, suggesting that they may affect prostate cancer progression and treatment through this mechanism. Basic research indicates that the gut microbiome also plays an important role in the underlying biology of prostate cancer through multiple mechanisms owing to the activity of microbial-derived metabolites and components. In this review, we describe the evidence surrounding the emerging relationship between the gut microbiome and prostate cancer, termed the “gut-prostate axis.”
3.Associations of homologous RNA-binding motif gene on the X chromosome (RBMX) and its like sequence on chromosome 9 (RBMXL9) with non-obstructive azoospermia.
Akira TSUJIMURA ; Kazutoshi FUJITA ; Kazuhiko KOMORI ; Phanu TANJAPATKUL ; Yasushi MIYAGAWA ; Shingo TAKADA ; Kiyomi MATSUMIYA ; Masaharu SADA ; Yoshihiko KATSUYAMA ; Masao OTA ; Akihiko OKUYAMA
Asian Journal of Andrology 2006;8(2):213-218
AIMTo investigate the associations of autosomal and X-chromosome homologs of the RNA-binding-motif (RNA-binding-motif on the Y chromosome, RBMY) gene with non-obstructive azoospermia (NOA), as genetic factors for NOA may map to chromosomes other than the Y chromosome.
METHODSGenomic DNA was extracted using a salting-out procedure after treatment of peripheral blood leukocytes with proteinase K from Japanese patients with NOA (n=67) and normal fertile volunteers (n=105). The DNA were analyzed for RBMX by expressed sequence tag (EST) deletion and for the like sequence on chromosome 9 (RBMXL9) by microsatellite polymorphism.
RESULTSWe examined six ESTs in and around RBMX and found a deletion of SHGC31764 in one patient with NOA and a deletion of DXS7491 in one other patient with NOA. No deletions were detected in control subjects. The association study with nine microsatellite markers near RBMXL9 revealed that D9S319 was less prevalent in patients than in control subjects, whereas D9S1853 was detected more frequently in patients than that in control subjects.
CONCLUSIONWe provide evidence that deletions in or around RBMX may be involved in NOA. In addition, analyses of markers in the vicinity of RBMXL9 on chromosome 9 suggest the possibility that variants of this gene may be associated with NOA. Although further studies are necessary, this is the first report of the association between RBMX and RBMXL9 with NOA.
Adult ; Chromosomes, Human, Pair 9 ; genetics ; Chromosomes, Human, X ; genetics ; Expressed Sequence Tags ; Heterogeneous-Nuclear Ribonucleoproteins ; genetics ; Humans ; Male ; Microsatellite Repeats ; genetics ; Nuclear Proteins ; genetics ; Oligospermia ; genetics ; Polymorphism, Genetic ; RNA-Binding Proteins ; genetics